Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Operating Expenses (2019 - 2023)

Historic Operating Expenses for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to $50.6 million.

  • ADC Therapeutics' Operating Expenses rose 16375.28% to $50.6 million in Q3 2023 from the same period last year, while for Dec 2023 it was $109.5 million, marking a year-over-year increase of 17117.48%. This contributed to the annual value of $4.8 billion for FY2022, which is 730.12% up from last year.
  • As of Q3 2023, ADC Therapeutics' Operating Expenses stood at $50.6 million, which was up 16375.28% from $58.9 million recorded in Q2 2023.
  • In the past 5 years, ADC Therapeutics' Operating Expenses registered a high of $4.8 billion during Q1 2022, and its lowest value of -$79.4 million during Q3 2022.
  • For the 5-year period, ADC Therapeutics' Operating Expenses averaged around $750.8 million, with its median value being -$35732.0 (2019).
  • Examining YoY changes over the last 5 years, ADC Therapeutics' Operating Expenses showed a top increase of 687987.69% in 2022 and a maximum decrease of 177915935.05% in 2022.
  • Over the past 5 years, ADC Therapeutics' Operating Expenses (Quarter) stood at -$35732.0 in 2019, then plummeted by 146625.62% to -$52.4 million in 2020, then surged by 99.85% to -$79791.0 in 2021, then decreased by 0.93% to -$80536.0 in 2022, then surged by 62981.2% to $50.6 million in 2023.
  • Its Operating Expenses was $50.6 million in Q3 2023, compared to $58.9 million in Q2 2023 and $3.7 billion in Q1 2023.